Galapagos NV (Euronext: GLPG) & (OTC: GLPYY)
Galapagos is specialized in novel modes-of-action, with a large pipeline of five Phase 2 (two led by GSK), one Phase 1, six pre- clinical, and more than 20 discovery small-molecule and antibody programs in cystic fibrosis, inflammation, antibiotics, metabolic disease, and other indications.
The Galapagos Group, including fee-for-service companies BioFocus, Argenta and Fidelta, has 800 employees and operates facilities in five countries, with global headquarters in Mechelen, Belgium.
Company Website: http://www.glpg.com/
Be the first to post on GALAPAGOS NV ORD NPV 0JXZ